Indications and uses
This is a natural Homeopathic remedy that helps relieve earache pain.
This is a natural Homeopathic remedy that helps relieve earache pain.
Adults: Allow 3 to 4 pellets to dissolve in mouth three times a day. Children under 12: Take 1/2 the adult dose. Do not exceed recommended dosage.
Ferrum phosphoricum 8X
Capsicum annuum 5X
Thuja occidentalis 5X
Silicea 8X
Mercurius vivus 8X
Kali phosphoricum 6X
Pyrogenium 12X
Manufactured according to the Homeopathic Pharmacopoeia of the United States (HPUS)
Earache Pain
This is a natural Homeopathic remedy that helps relieve earache pain.
If symptoms persist or worsen, discontinue use and contact a health professional.
As with any drug, if you are pregnant or nursing a baby, seek the advice of a health professional before using this product.
Keep this and all medications out of reach of children.
Adults: Allow 3 to 4 pellets to dissolve in mouth three times a day.
Children under 12: Take 1/2 the adult dose. Do not exceed recommended dosage.
Do not use if cap seal is broken.
Homeolab USA Inc., 3025 De L'Assomption Blvd., Montreal, QC H1N 2H2 Canada
PRODUCT OF CANADA
Lactose, sucrose
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 60512-2020-1 | 2025-12-31 | C162847 | 48780-1 | 9d75b9cf-da12-f424-e053-dadaa90a57ce | DRUG FACTS |
| 60512-2020-1 | 2020-01-31 | C162847 | 48780-1 | 9d75b9cf-da12-f424-e053-dadaa90a57ce | DRUG FACTS |
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 60512-2020 | EARACHE RELIEF (FERRUM PHOSPHORICUM, CAPSICUM ANNUUM, THUJA OCCIDENTALIS, SILICEA, MERCURIUS VIVUS, KALI PHOSPHORICUM, PYROGENIUM) PELLET [HOMEOLAB USA INC.] | 2 | Legacy NDC | 20131115_d2b35877-c410-4ecb-8b4e-54b639824d17.zip |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| CAPSICUM ANNUUM WHOLE | ACTIVE INGREDIENT | 7FKZ3QQQ1F | 2 | |
| FERRUM PHOSPHORICUM | ACTIVE INGREDIENT | 91GQH8I5F7 | 2 | |
| MERCURY | ACTIVE INGREDIENT | FXS1BY2PGL | 2 | |
| POTASSIUM PHOSPHATE, DIBASIC | ACTIVE INGREDIENT | CI71S98N1Z | 2 | |
| RANCID BEEF | ACTIVE INGREDIENT | 29SUH5R3HU | 2 | |
| SILICON DIOXIDE | ACTIVE INGREDIENT | ETJ7Z6XBU4 | 2 | |
| THUJA OCCIDENTALIS LEAFY TWIG | ACTIVE INGREDIENT | 1NT28V9397 | 2 | |
| CAPSICUM ANNUUM WHOLE | ACTIVE MOIETY | 7FKZ3QQQ1F | 2 | |
| COLLOIDAL SILICON DIOXIDE | ACTIVE MOIETY | ETJ7Z6XBU4 | 2 | |
| FERROSOFERRIC PHOSPHATE | ACTIVE MOIETY | 91GQH8I5F7 | 2 | |
| MERCURY | ACTIVE MOIETY | FXS1BY2PGL | 2 | |
| PHOSPHATE ION | ACTIVE MOIETY | NK08V8K8HR | 2 | |
| RANCID BEEF | ACTIVE MOIETY | 29SUH5R3HU | 2 | |
| THUJA OCCIDENTALIS LEAFY TWIG | ACTIVE MOIETY | 1NT28V9397 | 2 | |
| LACTOSE | INACTIVE INGREDIENT | J2B2A4N98G | 2 | |
| SUCROSE | INACTIVE INGREDIENT | C151H8M554 | 2 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 60512-2020 | 60512-2020-1 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| FERRUM PHOSPHORICUM | 91GQH8I5F7 | ACTIB |
| CAPSICUM ANNUUM WHOLE | 7FKZ3QQQ1F | ACTIM |
| THUJA OCCIDENTALIS LEAFY TWIG | 1NT28V9397 | ACTIB |
| SILICON DIOXIDE | ETJ7Z6XBU4 | ACTIB |
| MERCURY | FXS1BY2PGL | ACTIB |
| POTASSIUM PHOSPHATE, DIBASIC | CI71S98N1Z | ACTIB |
| RANCID BEEF | 29SUH5R3HU | ACTIB |
| SUCROSE | C151H8M554 | IACT |
| LACTOSE | J2B2A4N98G | IACT |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| SUCROSE | SUCROSE | C151H8M554 | SOLUTION / ORAL | 70000 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET / ORAL | 4249 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | SUSPENSION, EXTENDED RELEASE / ORAL | 5400 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | POWDER / RESPIRATORY (INHALATION) | 90 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | OINTMENT / TOPICAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 119.12 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET / BUCCAL | 296.7 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION / SUBCUTANEOUS | 47.75 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET / BUCCAL | 109 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | SOLUTION / RECTAL | 8 %w/v | ||
| LACTOSE | LACTOSE | J2B2A4N98G | INJECTION, POWDER, FOR SOLUTION / INTRAVENOUS | 133 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | POWDER, FOR SUSPENSION / ORAL | 40017 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | SUSPENSION / ORAL | 48209 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | GRANULE, FOR SUSPENSION / ORAL | 31885 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, CHEWABLE / ORAL | 1412 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, DELAYED RELEASE / ORAL | 160 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | INJECTION, POWDER, FOR SOLUTION / SUBCUTANEOUS | 133 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | WAFER / ORAL | 155.2 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, SUGAR COATED / ORAL | NA | ||
| LACTOSE | LACTOSE | J2B2A4N98G | POWDER / VAGINAL | 430 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / SUBCUTANEOUS | 308 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | INJECTION, SOLUTION / INTRAVENOUS | 0.45 %w/v | ||
| SUCROSE | SUCROSE | C151H8M554 | GRANULE, FOR SUSPENSION, EXTENDED RELEASE / ORAL | 18790 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CONCENTRATE / ORAL | NA | ||
| LACTOSE | LACTOSE | J2B2A4N98G | SUPPOSITORY / VAGINAL | NA | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, EXTENDED RELEASE / ORAL | 400 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | CAPSULE, EXTENDED RELEASE / ORAL | 619 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, EXTENDED RELEASE / ORAL | 284.54 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, FILM COATED / ORAL | 590 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | CAPSULE / ORAL | 3568 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | SOLUTION / RECTAL | 35.42 %w/v | ||
| SUCROSE | SUCROSE | C151H8M554 | CAPSULE, COATED PELLETS / ORAL | 59.8 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | FILM, EXTENDED RELEASE / TRANSDERMAL | 675 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | SOLUTION / ORAL | 1682 mg/15ml | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET / ORAL | 2500 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET / SUBLINGUAL | 109 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | DROPS / ORAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION / INTRAVENOUS | 1950 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | INJECTION / INTRAVENOUS | 203.5 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION, EMULSION / INTRAVENOUS | 970 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | CAPSULE, DELAYED RELEASE / ORAL | 955 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS | 2000 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, COATED / ORAL | 332.05 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, EFFERVESCENT / ORAL | 96.5 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | GRANULE / ORAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | TROCHE / BUCCAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | LOZENGE / BUCCAL | NA | ||
| LACTOSE | LACTOSE | J2B2A4N98G | INJECTION / INTRAMUSCULAR | 203.5 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTABLE, LIPOSOMAL / INTRAVENOUS | 7560 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 620 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CAPSULE, COATED PELLETS / ORAL | 135.2 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | POWDER / ORAL | 27768 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CREAM / VAGINAL | 3 %w/w | ||
| SUCROSE | SUCROSE | C151H8M554 | CONCENTRATE / ORAL | 4800 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | PASTILLE / ORAL | 426 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | SUSPENSION/ DROPS / ORAL | 3750 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | INJECTION, POWDER, FOR SOLUTION / INTRAMUSCULAR | 133 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, CHEWABLE / ORAL | 7258 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET / SUBLINGUAL | 352 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CAPSULE / ORAL | 530 mg |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 474246c9-2687-258f-e063-6294a90a485a | d2b35877-c410-4ecb-8b4e-54b639824d17 | 2025-12-31 | Warnings | d2b35877-c410-4ecb-8b4e-54b639824d17 |
Adverse event summaries are temporarily unavailable. Other product information remains available.